Shortness of breath? Learn more and get a better lung disease treatment plan with top experts. Visit our Online Expert Centers at
https://diagnosticdetectives.com/expe...
Exclusive interview / Dr. Anton Titov MD and Professor Dr. Aaron Waxman MD, leading pulmonary arterial hypertension, right heart failure and lung disease expert. Find out exact cause if you have shortness of breath - get a precise diagnosis and best treatment for shortness of breath root cause.
- Your research focuses on how blood vessels and lungs change in disease. You show that inflammation in lungs leads to change in vascular architecture, the lung undergoes, the blood vessels undergo remodeling process. You also have a mouse model that mimics closely the pulmonary arterial hypertension. So how does your research help people with lung disease? What are the current directions of your research in pulmonary arterial hypertension and other lung vascular diseases? I think the things that we've learned from some of the work we've done here, is really the role of inflammation in driving vascular remodeling. We've looked at several aspects of inflammation and we've used a number of models. You mentioned the mouse model that was an IL-6 over-producer that remodeled their lung blood vessels much like human disease. Although it's still not a clean model of human disease. Also in collaboration with Dr. Jane Leopold in cardiology, we've developed a large animal model using a pig model, where we can tie off the inferior pulmonary vein and that drives a timed remodeling of the pulmonary vascular bed and the right heart. So we've been able to use that as a model of progressive pulmonary vascular remodeling and kind of an accurate timing of right heart dysfunction and eventually right heart failure. And we've been able to look at different things like administering stem cells using an intracoronary approach and showing viability of those stem cells. That model may also allow us to ask the question about devices. And could we put in a ventricular assist device in the setting of right heart failure that might actually help remodel the vascular bed and obviously support the right ventricle? But questions about pulsatile blood flow versus non-pulsatile flow... There may be benefit to non-pulsatile blood flow in the pulmonary vascular bed. But I think getting back to your question about how it is affected how we treat patients, we right now start to do clinical trials in anti-inflammatory treatments, including anti IL-6 or medicines that affect targets to the IL-6 receptors and downstream effectors of those receptors as well as stem-cell approaches, and even device approaches.
- It's certainly very interesting because it has direct clinical implications and can help understand the pathophysiology of the lung disease better for patients with lung diseases.
Exclusive interview / Dr. Anton Titov MD and Professor Dr. Aaron Waxman MD, leading pulmonary arterial hypertension, right heart failure and lung disease expert. Find out exact cause if you have shortness of breath - get a precise diagnosis and best treatment for shortness of breath root cause.
- Your research focuses on how blood vessels and lungs change in disease. You show that inflammation in lungs leads to change in vascular architecture, the lung undergoes, the blood vessels undergo remodeling process. You also have a mouse model that mimics closely the pulmonary arterial hypertension. So how does your research help people with lung disease? What are the current directions of your research in pulmonary arterial hypertension and other lung vascular diseases? I think the things that we've learned from some of the work we've done here, is really the role of inflammation in driving vascular remodeling. We've looked at several aspects of inflammation and we've used a number of models. You mentioned the mouse model that was an IL-6 over-producer that remodeled their lung blood vessels much like human disease. Although it's still not a clean model of human disease. Also in collaboration with Dr. Jane Leopold in cardiology, we've developed a large animal model using a pig model, where we can tie off the inferior pulmonary vein and that drives a timed remodeling of the pulmonary vascular bed and the right heart. So we've been able to use that as a model of progressive pulmonary vascular remodeling and kind of an accurate timing of right heart dysfunction and eventually right heart failure. And we've been able to look at different things like administering stem cells using an intracoronary approach and showing viability of those stem cells. That model may also allow us to ask the question about devices. And could we put in a ventricular assist device in the setting of right heart failure that might actually help remodel the vascular bed and obviously support the right ventricle? But questions about pulsatile blood flow versus non-pulsatile flow... There may be benefit to non-pulsatile blood flow in the pulmonary vascular bed. But I think getting back to your question about how it is affected how we treat patients, we right now start to do clinical trials in anti-inflammatory treatments, including anti IL-6 or medicines that affect targets to the IL-6 receptors and downstream effectors of those receptors as well as stem-cell approaches, and even device approaches.
- It's certainly very interesting because it has direct clinical implications and can help understand the pathophysiology of the lung disease better for patients with lung diseases.
Pulmonary Arterial Hypertension and stem cells: how research helps patients (10) pulmonary hypertension review | |
Likes | Dislikes |
193 views views | followers |
Science & Technology | Upload TimePublished on 2 Jul 2018 |
Không có nhận xét nào:
Đăng nhận xét